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ABSTRACT
H-Prune  hydrolyzes short-chain polyphosphates (PPase activity) together with 
an hitherto cAMP-phosphodiesterase (PDE), the latest influencing different human 
cancers by its overexpression. H-Prune promotes cell migration in cooperation with 
glycogen synthase kinase-3 (Gsk-3β). Gsk-3β is a negative regulator of canonical 
WNT/β-catenin signaling. Here, we investigate the role of Gsk-3β/h-Prune complex 
in the regulation of WNT/β-catenin signaling, demonstrating the h-Prune capability 
to activate WNT signaling also in a paracrine manner, through Wnt3a secretion. In 
vivo study demonstrates that h-Prune silencing inhibits lung metastasis formation, 
increasing mouse survival. We assessed h-Prune levels in peripheral blood of lung 
cancer patients using ELISA assay, showing that h-Prune is an early diagnostic 
marker for lung cancer. Our study dissects out the mechanism of action of h-Prune 
in tumorigenic cells and also sheds light on the identification of a new therapeutic 
target in non-small-cell lung cancer.
INTRODUCTION
H-Prune belongs to the DHH family of 
phosphoesterases, and it is a human orthologue of 
Drosophila prune, through impairing the formation of 
drosopterins (red eye pigments). We have reported that 
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h-Prune cAMP-phosphodiesterase (PDE) activity is also 
involved in cell motility [1]. Kobayashi et al. showed 
interactions between h-Prune and Gsk-3β, reporting 
also that Gsk-3β inhibitors and small-interfering RNAs 
(siRNAs) for GSK-3 or h-Prune inhibit cell motility. These 
results suggested that h-Prune and Gsk-β cooperatively 
act to regulate cell motility [2]. Moreover, the minimal 
domains critical for interaction between h-Prune and Gsk-
3β was recently identified between residues Q356 and 
S396 of C-terminal h-Prune [3] .
H-Prune overexpression correlates with T and N 
stages in colorectal cancer; in addition, h-Prune expression 
is an independent predictor of survival of patients with 
gastric cancer [4]. Also, in an analysis of a large set of 
breast tumours, the pro-motility effects of h-Prune seen in 
vitro translated to significant association with lymph node 
status and metastasis formation in vivo, thus indicating 
that h-Prune provides a new marker of advanced stage 
breast carcinoma [5]. Misregulation of the Wnt signalling 
pathway is a hallmark of many human cancers, including 
lung cancer [6, 7]. Gsk-3β plays a leading role within the 
APC complex in initiating proteasomal degradation of β 
-catenin by phosphorylating it on key residues [8, 9]. 
In particular when APC complex or Gsk-3β activity 
is inhibited, the result is protein stabilization of β-catenin 
allowing it to translocate to the nucleus, where through 
the bind with TCF/LEF transcription factors, drives the 
transcriptional activation of genes involved in cell growth, 
invasion, the stem cell phenotype, and metastasis [8]. 
Here we studied h-Prune expression in lung cancer, 
showing its up-regulation during cancer progression. Then 
to better understand the molecular events in which h-Prune 
is involved and to clarify its effects on cell malignancy, 
we examined the role of h-Prune in the control of cell 
proliferation, cell cycle, apoptosis and cell invasion 
in vitro. Additionally, being h-Prune a binding partner 
for Gsk-3β, we investigated how h-Prune/Gsk-3beta 
interaction was able to affect Wnt signaling pathway.
 We demonstrated h-Prune capability to induce 
activation of canonical WNT/β-catenin signaling by 
promoting sequestration of Gsk-3β inside multivesicular 
bodies (MVBs), which are essential components of the 
WNT signal-transduction pathway [10], further showing 
the ability to activate WNT pathway in a paracrine 
manner, through Wnt3a increased secretion.
Finally, we evaluated the value of h-Prune and 
Wnt3a as tumour markers investigating their protein levels 
in peripheral blood of lung cancer patients. Here we show 
that the mechanism of action by which h-Prune enhances 
canonical WNT pathway activation, and its correlation to 
disease progression, provide the basis for the definition of 
a new diagnostic marker to detect NSCLC.
RESULTS
H-Prune protein expression enhances WNT 
pathway activation
H-Prune interacts with Gsk-3β, and together they 
are involved in regulation of cell migration through 
the modulation of focal adhesions [2]. In-vitro binding 
studies using recombinant proteins have demonstrated 
that the carboxy-terminus amino-acid region 333-453 of 
h-Prune is necessary and sufficient for complex formation 
with Gsk-3β, with the identification of a minimal region 
of interaction of the h-Prune protein [2, 3]. Moreover, 
one of the main functions of Gsk-3β is the regulation of 
β-catenin turnover in the WNT signaling pathway. For this 
reason, we asked whether the h-Prune/Gsk-3β interaction 
can also be identified in lung cancer cell lines, and if 
this interaction has a role in canonical WNT signaling. 
First, we performed co-immunoprecipitation assay and 
observed that endogenous Gsk-3β interacts with h-Prune-
Flag in A549 lung cancer cell line (Supplementary Fig. 
S1a). Next, we examined whether the interaction between 
h-Prune and Gsk-3β has a functional role for TCF 
transcriptional activity. To evaluate this, we used TOP-
FLASH reporter [11] assays in the HEK293 cell line, in 
which we observed low levels of the endogenous h-Prune 
protein (Supplementary Fig. S1c). As shown in Figure 
1a, compared to the empty vector transfected cells, there 
were high levels of endogenous β-catenin transcriptional 
activity in HEK293 cells transfected with h-Prune full-
length (aa 1-453; P= 9.4e-06) and h-Prune C-terminal 
region (aa 334-453; P= 2e-05). To ensure that TOP-FLASH 
activation was due to h-Prune/Gsk-3β interaction, we 
also transfected HEK293 cells with plasmid encoded 
h-Prune N-terminal region (aa 1-333), that does not bind 
Gsk-3β, as demonstrated by Kobayashi and colleagues 
[3]. Our results demonstrated that there wasn’t TOP-
FLASH activation in h-Prune N-terminal transfected 
cells, thus strengthening our hypothesis. The additional 
data presented in Supplementary Fig. S1d show that 
h-Prune can activate the TOP-FLASH in a dose-dependent 
manner, thus showing that h-Prune is an activator of WNT 
signaling.
To gain insight into the mechanism accounting 
for the enhancement of β-catenin-mediated TCF 
transcriptional activity in HEK293 cells, we also 
used several known Gsk-3β inhibitors coupled with 
h-Prune transfection, to evaluate whether or not there 
was further enhancement of the activation of TCF 
transcriptional activity. Figure 1b shows the enhancement 
of transcriptional activity in the h-Prune-transfected cells, 
and in cells transfected with plasmid encoding h-Prune and 
also treated with SB-216763, Chiron-99021 and/or insulin 
growth factor-1 (IGF-1). This was not observed using 
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Figure 1: H-Prune expression enhances Wnt pathway activation. (a) Full-length h-Prune (aa 1-453) and h-Prune C-terminal 
region (aa 334-453) stimulation of HEK293 cells induces β-catenin-mediated transcriptional activity. The cells were transfected with the 
TOP/FOP flash plasmid and the Renilla luciferase plasmid overnight. The data were normalized to Renilla luciferase activity. Full-length 
h-Prune and h-Prune C-terminal region increased TCF transcriptional activity in HEK293 cells compared to empty vector and h-Prune 
N-terminal region (1-333). (b) TOP/FOP luciferase assay that shows that h-Prune induces β-catenin–mediated transcriptional activity 
through a GSK-3β–dependent mechanism in HEK293 cells. The cells were co-transfected with the TOP/FOP luciferase reporter, the renilla 
luciferase plasmid, and the control or h-Prune vector. A day after infection, the cells were treated overnight with vehicle, SB216763 (10 
μM), Chiron99021 (10 μM) and IGF-1 (1 ng/ml per 5h). The data were normalized to Renilla luciferase activity and are expressed as fold-
increase over vector-transfected control cells, expressed as means ±SD of three independent experiments, each carried out in triplicate. 
(c) Total protein prepared from HEK293 cells transfected with control vector or full-length h-Prune, which were exposed to NH4Cl (30 
mM) for different times, and were subjected to Western blotting with an anti-GSK3-β antibody. α-Tubulin was used as the loading control, 
and an anti-Flag antibody provided the transfection control. (d) Western blots of protease protection assay in empty-vector-and h-Prune-
transfected HEK293 cells. Cells were digitonin-permeabilized, and membranes were isolated and incubated without or with proteinase K in 
the absence or presence of Triton X-100. Gsk-3β was protected from Proteinase K in h-Prune overexpressing cells, but only in the absence 
of Triton X-100. (e) Representative images from immunofluorescence analysis of HEK293 cells transfected with plasmid encoding full-
length h-Prune and stained for Gsk-3β and the early endosome marker EEA1 (ii), and for h-Prune and EEA1 (i). Scale bars, 10 µm. (iii, iv) 
Representative images from immunofluorescence analysis of HEK293 cells transfected with the plasmid encoding full-length h-Prune, and 
stained for Gsk-3β and the late endosome marker Rab7 (iv), and for h-Prune and Rab7 (iii). Scale bars, 20 µm. 
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β-catenin cDNA transfection in these cells. The simplest 
explanation would be that there is a cooperative effect 
between h-Prune and the other drugs used here, for the 
inhibition of β-catenin degradation by Gsk-3β. Moreover, 
both increased expression levels of active β-catenin and 
inhibition of its degradation were enhanced by h-Prune 
overexpression, as additionally confirmed by the Western 
blotting (Supplementary Fig. S1e and f). Collectively, 
these data demonstrate that the binding of h-Prune and 
Gsk-3β is sufficient to mediate the inhibition of β-catenin 
degradation, thus leading to an enhancement of the free 
β-catenin levels for its translocation into the nucleus and 
the activation of WNT signaling.
H-Prune overexpression leads to increased Gsk-3β 
sequestration inside multivesicular bodies
Taelman and colleagues demonstrated that Gsk-3β 
sequestration inside MVBs is a key step in WNT/β-catenin 
signaling activation [10]. In this study, we explored 
whether h-Prune can induce Gsk-3β sequestration inside 
MVBs. To investigate this, we first treated HEK293 
cells with NH4Cl, a known inhibitor of acidification and 
organisation of the endosomal compartments [13]. This 
treatment was carried out 36 h post-transfection with a 
control empty vector and a plasmid encoding h-Prune, 
with the cells harvested at different times. As shown 
in Figure 1c, 0.5 h and 1 h after NH4Cl administration 
there was an increase (with 2-fold increase with respect 
to Time 0, as shown by densitometric analyses) in Gsk-
3β protein levels in the h-Prune-overexpressing cells, as 
compared to empty-vector-transfected cells, suggesting an 
increase of Gsk-3β in endosomal compartment in h-Prune-
ovexpressing cells. Next, we performed a protease 
protection assay, the golden standard analysis to determine 
the localization of a protein in a membrane-bounded 
compartment. Here, the Gsk-3β and h-Prune proteins 
were protected from proteinase K digestion after h-Prune 
transfection in HEK-293 cells, as compared to the empty-
vector-transfected cells (Figure 1d). This phenomenon 
whereby h-Prune provides protection against proteinase K 
degradation of Gsk-3β was abolished when the membranes 
were solubilized with Triton X-100. Furthermore, in 
h-Prune-overexpressing cells, fluorescence microscopy 
(Figure 1e) showed co-localisation of Gsk-3β and Flag-
tagged h-Prune with the early and late endosomes markers 
(EEA1 and Rab7), thus leading us to speculate upon a 
physical interaction between h-Prune and GSK-3β, such 
that both of these proteins move into endosomes during 
WNT activation. 
H-Prune-conditioned medium induces WNT 
signaling
The activation of TCF/LEF transcription has been 
shown to have negative and positive feedback loops on 
WNT pathway activation [14, 15]. To investigate whether 
h-Prune overexpression has this signal-inducing activity, 
we first quantified the expression levels of several WNT 
proteins, both canonical and non canonical, in HEK293 
cells following h-Prune transfection (Supplementary 
Fig. S2a). The qPCR showed that the overexpression 
of h-Prune significantly enhanced WNT3a expression 
to a level 4-fold the control (P=0.045; Supplementary 
Fig. S2a), while there were no significant differences in 
the mRNA expression of the other analyzed cytokines. 
Therefore, we evaluated WNT3a protein expression levels, 
which confirmed the mRNA expression results (Figure 
2a). These results led us to investigate whether there 
was an enhancement of Wnt3a release that could exert 
paracrine effects on the other adjacent cells. To evaluate 
these paracrine effects induced by h-Prune overexpression, 
conditioned medium of h-Prune-transfected cells was 
added to cells transiently transfected with the TCF/LEF 
reporter. As shown in Figure 2b, by comparing the TCF/
LEF transcriptional reporter activity in HEK-293 cells, 
we observed that the addition of medium from cells 
transfected with the plasmid encoding h-Prune led to six-
fold induction of WNT activity, whereas no induction 
was observed by adding medium from empty-vector-
transfected cells (P= 0.003). Under the same conditions, 
the addition of Wnt3a neutralizing antibody downregulated 
reporter activity in HEK293 cells incubated with h-Prune 
overexpressing cells conditioned medium to levels similar 
to that observed in cells treated with CM from empty 
vector-transfected cells. If h-Prune-conditioned medium 
can lead to the activation of WNT signaling, we reasoned 
that h-Prune can induce cytokine release that in turn will 
activate the signals, thus influencing adjacent cells in a 
paracrine manner. Furthermore, to confirm the release 
of Wnt3a into the cell medium, we performed an ELISA 
for Wnt3a. Here, the HEK293 cells were transfected 
with a plasmid encoding full-length h-Prune (aa 1-453), 
the h-Prune C-terminal region (aa 334-453 responsible 
for binding with GSK3-β) or the h-Prune N-terminal (aa 
1-333) as control. When compared to transfection with 
the empty vector, we observed significant enhancement 
(h-Prune full length versus empty vector P= 3.7 e-05; 
h-Prune C-terminal region versus empty vector P= 8.3 e-05) 
of the release of the cytokine Wnt3a into the medium (Fig. 
2c; Supplementary Fig. S3a). While, as expected, when 
compared the transfection with plasmid encoding h-Prune 
N-terminal to empty vector, no significant enhancement 
of the release of the cytokine Wnt3a into the medium was 
observed (P= 3.7 e-05). 
In our previously reported data, we showed 
enhancement of Wnt3a levels following h-Prune 
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over-expression. Here, to exclude further that nuclear 
translocation of β-catenin is exclusively due to the positive 
feedback within the cell by Wnt3a, we used niclosamide, 
which is known to damage Wnt3a/β-catenin signaling 
activation by inducing LRP6 protein degradation [16]. 
First, we evaluated the active β-catenin protein levels upon 
0.6 μM niclosamide treatment in both empty vector- and 
h-Prune-overexpressing HEK293 cells. Western blotting 
demonstrates that h-Prune can increase the protein levels 
of active β-catenin even in niclosamide-treated cells, 
unlike what was seen in the empty-vector-transfected 
cells (Fig. 2d). Then, we determined whether h-Prune-
conditioned medium still activated canonical WNT 
signaling in these niclosamide-treated cells. Interestingly, 
addition of conditioned medium from h-Prune-transfected 
HEK293 cells resulted in increased levels of active 
Figure 2: H-Prune–conditioned medium induces Wnt signalling activation. (a) Western blotting showing that overexpression 
of h-Prune leads to increased Wnt3a expression, as compared to empty-vector-transfected cells. The efficiency of transfection was assessed 
using an anti-Flag antibody. α-Tubulin was used as the loading control. (b) TOP/FOP assay performed on reporter cells stimulated with 
equal amounts of conditioned medium (CM) from HEK293 cells transfected with either the empty vector plasmid or the plasmid encoding 
h-Prune. *P = 0.01. Treatment with the anti-Wnt3a antibody reduced activation of TOP/FOP in cells receiving conditioned medium from 
HEK293 cells transfected with the plasmid encoding h-Prune. This further indicates that Wnt3a released into the medium can activate the 
Wnt signaling in the neighbouring cells in a paracrine manner. (c) ELISA to determine Wnt3a release in the medium from HEK293 cells 
transfected with the empty vector plasmid or plasmids encoding full-length h-Prune (aa 1-453), h-Prune C-terminal region (aa 334-453) 
or h-Prune N-terminal region (aa 1-333). ***P>0.0005. (d) Total protein prepared from HEK293 cells after transfection with the control 
vector or full-length h-Prune, which were exposed to niclosamide (0.6 μM) for 6 h were subjected to Western blotting with anti-β-catenin 
and active β-catenin antibodies. α-Tubulin was used as the loading control and anti-Flag antibody provided the transfection control. (e) 
HEK293 cells were stimulated for 6 h with conditioned media (CM) from HEK293 cells transfected with empty vector and h-Prune vector. 
Niclosamide or DMSO (as control) were added to the conditioned media. Protein extracts were loaded onto acrylamide gels and subjected 
to Western blotting with anti-β-catenin, active β-catenin, GSK3-β and pSer9 GSK3-β antibodies. α-Tubulin protein levels were used as 
the loading control. (f) HEK293 cells were stimulated for 6 h with conditioned media (CM) from HEK293 cells transfected with empty 
vector and h-Prune vector. The protease protection assay shows Gsk-3β protected from Proteinase K in cells receiving CM from h-Prune 
overexpressing cells. 
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β-catenin (Fig. 2e) in the receiving HEK293 cells. 
Furthermore, addition of niclosamide to the conditioned 
medium led to a reduction in active β-catenin levels in 
cells that received the conditioned medium from the 
empty-vector-transfected and h-Prune-transfected cells. 
Several studies demonstrated that Wnt3a induces 
endocytosis of Gsk-3β into MVBs, thus leading to WNT 
pathway activation [10, 17]. This result was reproduced in 
HEK293 cells treated for 6 hours with conditioned medium 
from empty vector and h-Prune overexpressing cells. 
The results in figure 2f show that h-Prune conditioned 
medium is able to induce Gsk-3β uptake into MVBs in the 
receiving HEK293 cells. While in cells receiving CM from 
control cells, we didn’t observe this phenomenon. Overall, 
these data strengthen our previous findings, confirming 
that h-Prune can activate the canonical WNT/β-catenin 
signaling through Gsk3β interaction and is also capable of 
inducing the activation of WNT signalling in a paracrine 
manner through the release of Wnt3a into the medium. 
H-Prune promotes β-catenin nuclear translocation 
through a GSK-3β–dependent mechanism
In the WNT/β-catenin pathway, the N-terminal 
phosphorylation of β-catenin by GSK-3β is a key control 
point for ubiquitin-dependent β-catenin degradation [18]. 
To gain further insight into the mechanism of β-catenin 
nuclear translocation mediated by h-Prune, we asked 
whether h-Prune is necessary for β-catenin degradation in 
lung cancer cells.
If h-Prune impairs GSK-3β activity, we speculated 
that the negative effects of h-Prune knockdown on 
β-catenin activation should be ameliorated by the loss of 
functional activity of GSK-3β. To test this hypothesis, we 
examined the consequences of the treatment of h-Prune-
knockdown A549 cells with LiCl, a specific inhibitor of 
Gsk-3β (Fig. 3a and b). To achieve this, using LiCl, we 
evaluated the levels of active β-catenin and phospho-Gsk-
3β (on Ser9) in a cellular context without and with h-Prune 
expression, and at different times. In these assays, LiCl 
stimulation led to early activation of β-catenin at 30 min of 
treatment, followed by increased β-catenin protein levels 
between 2 h and 4 h post-treatment. We thus observed 
that the protein levels of phospho-Gsk-3β (Ser9) were up-
regulated at the same time after induction in cells infected 
with an unrelated shRNA (sh-UNR). On the other hand, in 
AdV-Sh-Prune-infected cells, where the levels of phospho-
Gsk-3β were already decreased, there were no substantial 
variations in the activation of β-catenin, and nor was there 
any enhancement of phospho-Gsk-3β (Ser9) protein levels 
at either 2h and 4h of treatment (Fig. 3a and b). Altogether 
these data indicate that β-catenin nuclear translocation 
followed by LiCl-induced canonical WNT signaling 
activation in lung cancer cells requires the h-Prune 
Figure 3: Regulatory mechanism of h-Prune on Gsk-3β. (a and b) Effects of LiCl (20 mM) on β-catenin nuclear translocation 
and phosphorylation status of Gsk-3β in A549 AdV-Sh-UNR- and AdV-Sh-Prune-infected cells for different times was assayed by Western 
blotting analysis (a). Densiometric time-course analysis (pSer9-Gsk-3β), as β-actin normalized. Data are means ±standard deviation of 3 
experiments, each carried out in triplicate (b). (c) After h-Prune depletion in H1299 and A549 cells, Western blotting detected decreased 
expression of active β-catenin and pSer9-Gsk-3β. Total β-catenin, total Gsk-3β and β-actin were used as the loading controls. (d) Expression 
levels of Cyclin D1, Survivin, CD44 and c-Myc decreased with h-Prune silencing. β-Actin was used as the loading control.
Oncotarget5742www.impactjournals.com/oncotarget
inhibitory effects on Gsk-3β activity. Furthermore, the 
results presented here suggest that h-Prune/Gsk-3β 
binding results in significant alteration to WNT/β-catenin 
signaling.
WNT pathway impairment by h-Prune silencing 
in lung cancer cell lines
We additionally evaluated the effects of h-Prune 
silencing on WNT target genes. For this purpose, we used 
AdV-Sh-Prune and an adenovirus containing an unrelated 
shRNA (AdV-Sh-UNR). Both of these were constructed 
such that they could be followed through internal 
ribosomal entry site-driven green florescent protein 
(GFP). H1299 and A549 lung cancer cell lines were then 
transduced by infection with adenovirus particles, and 24 
h later, the efficiency of infection was evaluated through 
GFP expression (Supplementary Fig. S4b). At 72 h after 
infection, in AdV-Sh-Prune–infected lung cancer cell lines, 
h-Prune was significantly down-regulated (Fig. 3c), while 
no inhibition was observed in the AdV-Sh-UNR–infected 
cells. As shown in Figure 3c, the expression of active 
β-catenin was reduced upon h-Prune down-regulation, 
while the levels of total β-catenin were unchanged. 
Consistent with these data, we also observed that the 
protein levels of cyclin D1, Survivin, CD44, and c-Myc, 
as targets of canonical WNT signaling, were significantly 
down-regulated in these AdV-Sh-Prune–infected A549 and 
H1299 cells, with respect to the Adv-Sh-UNR–infected 
cells (Fig. 3d). Furthermore, by silencing the endogenous 
h-Prune in H1299 and A549 cells, there were reduced 
mRNA expression levels of Birc5, c-Myc and CD44, 
supporting the concept that h-Prune regulates these targets 
via inhibition of transcription (Supplementary Fig. S4c). 
Altogether, these data demonstrate that while h-Prune 
overexpression leads to canonical WNT activation, 
conversely, its loss of function through RNA interference, 
leads to an impairment of WNT activity in lung cancer cell 
lines that then inhibits several target proteins downstream 
of this inhibition.
h-Prune silencing influences proliferation and soft 
agar colony formation in lung cancer cells
We then assay dynamics of cell growth and 
proliferation. Using cell index assays, we confirmed 
that with both of these lung cancer cell lines, when they 
were infected with AdV-Sh-Prune they showed impaired 
proliferation, compared to AdV-Sh-UNR–infected cells 
(Fig. 4a). Soft agar colony-formation assays were then 
performed to determine whether down-regulation of 
h-Prune reduces colony formation in an anchorage-
independent culture system (Fig. 4b). In these assays, 
the number of colonies of the AdV-Sh-UNR–infected 
versus AdV-Sh-Prune–infected H1299 cells were 
significantly reduced: 217 (±16.9) versus 104.5 (±24.7), 
respectively (P= 0.03). There was a similar significant 
reduction in the infected A549 cells: 91.5 (±4.9) versus 
57.5 (±9.19), respectively (P= 0.04; Fig. 4b). Therefore, 
h-Prune silencing also reduces anchorage-independent cell 
proliferation of lung cancer cells. 
In-vivo lung metastasis assay using xenografts in 
nude mice
As h-Prune silencing suppressed the invasion 
and proliferation of NSCLC cells in vitro, we sought 
to investigate whether h-Prune silencing can inhibit 
metastases formation of lung cancer cells in-vivo using 
a mouse lung metastasis model. To achieve this, we 
assayed two groups of xenograft mice that were tail-vein 
injected with A549-Luc cells (A549 cells stabilised for 
the expression of the luciferase gene); these cells were 
previously infected with the control AdV-Sh-UNR or 
AdV-Sh-Prune. Tumorigenesis was followed using in-
vivo biolumuniscence imaging (BLI) technology, over 11 
months. The mice receiving AdV-Sh-Prune-treated A549-
Luc cells (6 mice) showed significant reduction of tumour 
burden (Fig. 4c) compared to the control treated group 
(AdV-Sh-UNR, 6 mice). 
In the same experiment, we investigated the survival 
rates of these mice. The animals were observed daily until 
their death. At month 11, all of the surviving mice were 
sacrificed and their lungs were excised and stained with 
Bouin’s solution, with the incidence of tumour nodules 
examined macroscopically. As shown in Figure 4c, 
compared to the control A549 lung cancer cells that were 
treated through AdV-Sh-UNR infection, silencing h-Prune 
expression in these cells resulted in decreased lung 
metastasis nodules, thus further suggesting that h-Prune 
is a positive regulator of cancer invasion and metastasis 
formation in vivo. Moreover, the Kaplan-Meier survival 
curves for these treated mice revealed that the silencing 
of h-Prune directly and significantly correlates to overall 
survival (P= 0.005) (Fig. 4d). Taken altogether, our data 
demonstrate that h-Prune is necessary to maintain the 
level of malignancy in lung cancer, in terms of tumour 
metastasis formation, invasion and growth.
h-Prune expression in human NSCLC tissues 
To assess the expression levels of h-Prune in patients 
with NSCLC, we tested a cohort of 45 human tumour 
samples that had been flash-frozen after biopsy and before 
RNA isolation. The sample collection was composed 
of the predominant histotypes of NSCLC. H-Prune 
expression levels in the tumour tissues were assessed 
using a custom-made Illumina microarray platform, and 
these were compared with the levels in the corresponding 
normal adjacent tissue (Supplemental Table S1). Of the 
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36 samples analysed, significantly increased h-Prune 
expression levels were seen in tumour tissues (stage I and 
stage II; n = 28) compared to the corresponding normal 
adjacent lung tissues (n = 8; P=0.018) (Supplementary 
Fig. S6a). To additionally validate the microarray gene-
expression data, the relative expression of h-Prune was 
determined by qRT-PCR analysis of 33 samples from 
the same dataset (as 8 normal tissues and 25 tumour 
tissues). These were combined with a second dataset of 
12 lung tissues (as 7 normal tissues and 5 tumour tissues) 
for a total of 30 tumour and 15 normal samples. These 
thus confirmed the previous expression data, showing 
higher h-Prune expression levels in stage I-II lung cancer 
tumours (P=0.008), compared to the normal lung tissues 
(Supplementary Fig. S6b). Moreover, after analysis, the 
overexpression of h-Prune was also observed in additional 
published lung cancer dataset [19-22], as reported in 
Supplemental Figure S6c.
Immunohistochemical analysis of h-Prune in lung 
cancer
Immunohistochemical analysis of h-Prune has 
been reported in several types of cancers [5, 23]. We next 
sought to determine whether h-Prune overexpression 
indeed contributes to β-catenin activity in lung cancer 
Figure 4: H-Prune silencing effects on proliferation of lung cancer cells. (a) Normalized cell index as a measure of proliferation 
of A549 (upper) and H1299 (lower) cells treated with AdV-Sh-UNR and AdV-Sh-Prune. Data are means ± SD. (b) A549 and H1299 cells 
were infected with AdV-Sh-UNR and AdV-Sh-Prune and plated at 1.5×105 cells/well in six-well plates for the soft agar colony assays. Data 
are means ±SD (n = 2). H-Prune silencing decreased the soft agar colonies in both lung cancer cells (*P = 0.04 and 0.03, respectively). (c) 
The AdV-Sh-UNR (6 mice) or AdV-Sh-PruneA549_Luc cells were injected into SCID mice by tail-vein injection, and lung colonization 
were bioluminescently imaged at the time of injection (T0) and after 11 months (T1) (left). Representative images of the lungs of A549-Luc 
AdV-Sh-UNR and AdV-Sh-Prune–treated mice, macroscopically examined (in the middle) and stained with hematoxylin-eosin after death 
(A549-Luc AdV-Sh-UNR–treated mice) or at the end of the trial (AdV-Sh-Prune–treated mice) (right). (d) Kaplan-Meier survival curves 
for nude mice tail-vein injected with A549_Luc AdV-Sh-UNR (6 mice) or AdV-Sh-Prune (6 mice). 
Oncotarget5744www.impactjournals.com/oncotarget
tissues. For this purpose, we determined both h-Prune 
and active β-catenin expression in 33 primary human 
lung cancer tissues using immunohistochemical staining 
assays. It has been well documented that the β-catenin 
accumulated in the cytoplasm and/or the nucleus increases 
when cells have stabilised β-catenin and, consequently, 
activated β-catenin/TCF activity. In contrast, when 
β-catenin is mainly localised at the plasma membrane 
of cells, it is known that the transactivation activity is 
low. As shown in Figure 5a, there were low h-Prune and 
β-catenin protein expression levels in normal adult lung 
tissues. In contrast, h-Prune expression was detectable in 
30 of 30 (100%) lung cancer samples. Of those positive 
samples, 5 showed limited reactivity (score +1), 4 showed 
moderate reactivity (score +2), and 21 (70%) showed 
strong reactivity (score +3). In most cases, the h-Prune 
staining was also localized to the cytoplasm. In all, 90% 
of the tissues also showed positive immunohistochemical 
staining for β-catenin. We also observed no significant 
variations in the h-Prune expression patterns between the 
different histological types of lung cancer (Supplementary 
Table S2). Altogether, these data not only support our 
previous molecular data, but also further strengthen the 
clinical biological significance of h-Prune expression in 
lung cancer patients.
Serum levels of h-Prune expression in lung cancer 
patients
To date, most lung cancer patients are diagnosed at 
an advanced stage of disease, making curable surgery not 
an option; thus, early diagnosis and effective treatment 
are key to prolong the survival of lung cancer patients. 
To evaluate the importance and potential of h-Prune 
as an early tumour marker in lung cancer, a total of 14 
lung cancer patients (stage I-II) (Supplementary Table 
S3) and 14 healthy controls were enrolled in this study 
and the serum levels of h-Prune were assessed using 
Figure 5: H-Prune is overexpressed in human NSCLC. (a) Representative paraffin sections analyzed by immunohistochemistry 
using a home-made anti–h-Prune rabbit polyclonal antibody. (i) Immunostaining of lung normal tissue (200×). No immunoreactivity was 
observed. (ii) Immunostaining of a carcinoid tissue (400×). Hyperplastic cells show weak cytoplasmic staining. (iii) Immunostaining of 
a lung adenocarcinoma (200×). Cytoplasmic staining was observed. (iv) Immunostaining of a squamous cell lung carcinoma (200×). 
Cytoplasmic positivity was observed in malignant cells. (b) Box plot showing the serum h-Prune levels in 14 healthy controls and 14 
patients with stage I-II NSCLC (***P> 0.0005). (c) Box plot showing the serum h-Prune levels in 14 healthy controls and 80 patients 
(***P> 0.0005). (d) Box plot showing the serum levels of Wnt3a in 10 healthy controls and 24 patients (*P= 0.03). 
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ELISA assays. As shown in figure 5b, h-Prune serum 
concentrations was observed to be significantly higher 
(P< 0.0005) in patients with stage I and II NSCLC than in 
the healthy controls (mean, 291.2±162 pg/ml and 99.3±52 
pg/ml, respectively). The area under the ROC curve 
(AUC), as the measure of the diagnostic performance, 
was 0.95 (Supplemental Figure S7b). The sensitivity and 
specificity at a cut-off of 151,2 pg/ml were 93% and 79%, 
respectively. 
Then, we compared the serum levels of h-Prune 
in additional lung cancer patients (n = 80, including 
stages I-IV) with healthy controls (n = 14) (Fig. 5c) 
(Supplementary Table S4). Serum concentrations of 
h-Prune ranged from 98.8 pg/ml to 980 pg/ml (mean, 
294.2±191.2 pg/ml) in lung cancer patients and from 19.5 
pg/ml to 183.2 pg/ml (mean, 99.3±52.3 pg/ml) in healthy 
controls. The area under the curve (AUC) as depicted by 
the ROC curve was 0.888. The sensitivity and specificity 
at a cut-off of 130.1 pg/ml were 83.8% and 71.4%, 
respectively (Supplementary Fig. S7c and d). Our results 
demonstrated that h-Prune levels were significantly higher 
in the lung cancer patients, and even more interesting in 
patients with early stages of NSCLC, than in the healthy 
controls (P< 0.0005; Fig. 5b-c). 
We than asked whether the patients who had high 
serum levels of h-Prune showed also high serum levels 
of Wnt3a. For this reason, the serum levels of Wnt3a in 
lung cancer patients (n = 24) and healthy controls (n = 
10) were assessed using ELISA assays. As expected, 
serum concentrations of Wnt3a in lung cancer patients 
was higher than in healthy controls (P= 0.03; Fig. 5d). 
The area under the curve (AUC) was 0.72. The sensitivity 
and specificity at a cut-off of 198.3 pg/ml were 95.8% 
and 60%, respectively (Supplementary Fig. S7e and 
f). Overall, the results showed that the use of Wnt3a as 
serum lung tumor marker had good specificity but poor 
sensitivity (Supplementary Table S5), in contrast, the 
sensitivity and the specificity of h-Prune detection alone 
is sufficient to identify lung cancer affected patients. In 
conclusion, we think that the combined use of h-Prune 
and Wnt3a can be of impact for lung cancer diagnosis 
improving sensitivity and specificity. These analyses 
require future efforts.
DISCUSSION
A key observation in this study was that h-Prune 
is an important regulator of WNT signaling in lung 
cancer. The activation of the WNT pathway in lung 
cancer has been shown to contribute to growth and 
survival of lung cancer cell lines [24-27] and to promote 
tumor aggressiveness and resistance to chemotherapy 
and radiation. A recent study showed that the h-Prune 
C-terminal region includes an intrinsic disorder protein 
domain that confers the ability to bind to several different 
ligands [12]. Perhaps one of the most interesting features 
of disordered proteins is their functionality that involves 
binding to a partner ligand and then this interaction is 
associated with the induction of folding in the previously 
disordered structure [28]. This feature makes h-Prune 
Figure 6: Proposed model of h-Prune action in cancer cells. H-Prune binds to Gsk-3β to induce β-catenin nuclear translocation 
(1). As a consequence, the activation of the WNT transcriptional program promotes transcription (2) and then the release of Wnt3a (3), 
which has positive feedback on its own activation (autocrine) (4). Wnt3a released from the h-Prune overexpressing cells also has a paracrine 
effect on the other cells, leading to activation of this downstream signalling (5). These events drive h-Prune and Gsk-3β into multivesicular 
endosomes, further decreasing the activity of Gsk-3β in the cytosol.
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an important binding partner for many proteins. Indeed, 
h-Prune has different binding proteins, among which, 
there is Gsk-3β. The h-Prune interaction domain with Gsk-
3β was recently identified using NMR [3]. 
Here we demonstrated how h-Prune, through 
its binding with Gsk-3β, takes part to the WNT/β-
catenin pathway activation. Our results demonstrated 
that the interaction between h-Prune and Gsk-3β could 
potentially led to an impairment of capability of Gsk-
3β to phosphorylate β-catenin. In this way, β-catenin 
may be not phosphorylated and becomes stabilized, 
accumulating in the nucleus, thus leading to activation 
of the WNT transcriptional programme. It is in fact 
consistent with our data that, as consequence of TCF/
LEF activation induced by h-Prune, Wnt3a mRNA and 
protein expression increases, increasing also the release 
of the cytokine into the medium, as assessed by Elisa 
assay. Our data further show that Wnt3a up-regulation 
has as a positive consequence an enhancement of both 
autocrine and paracrine WNT signaling activation that 
drive h-Prune and Gsk-3β into multivesicular endosomes, 
further decreasing the activity of Gsk-3β in the cytosol, 
as hypothesized in the model presented in Fig. 6. Wnt 
signaling is regulated at different levels by a large number 
of effectors, either intracellularly or extracellularly, that 
could act as antagonists or agonists. The same β-catenin 
signaling leads to the activation of either positive and 
negative feedback pathways [14,15]. Negative feedback 
mechanisms serve to restrict the duration or spread 
of the signaling event following the initial stimulus. 
For these reasons, we determined whether h-Prune 
activation of β-catenin signaling would also result in the 
activation of negative feedbacks, investigating changes in 
Axin2 and Dkk1 expression levels. However under our 
experimental conditions we did not observe increased 
expression levels of Axin2 and Dickkopf1 (dkk1) upon 
h-Prune overexpression (Supplementary Fig. S2c and 
d). In conclusion, we presented the evidence that Wnt3a 
cytokine is regulated by h-Prune, but further experiments 
are clearly needed to address mechanistically the early 
phases of this point. After characterizing the mechanism 
by which h-Prune induces WNT pathway activation in 
HEK293, cells chosen because they have an intact WNT 
network and are responsive to canonical ligands, including 
Wnt3a [8], we dissected out the function of h-Prune in lung 
cancer cell lines, confirming the previous results obtained 
in HEK293 cells. In fact, the h-Prune silencing promotes 
decreased proliferation and invasion in H1299 and A549 
cells. We thus show that the levels of active β-catenin and 
the major downstream targets of the WNT pathway were 
severely down-regulated after h-Prune depletion, while 
the addition of h-Prune in these lung cancer cells lead to 
increase expression of active β-catenin. Together, all these 
findings are consistent with the involvement of h-Prune 
to enhance and sustain the WNT canonical pathway. 
Moreover, h-Prune depletion resulted in inhibition of 
metastases formation, which provided useful clues for 
the description of its mechanism of action in the invasion 
and metastasis formation properties of lung cells. Thus, 
an impairment of the expression of endogenous h-Prune 
results in the loss of lung cancer metastasis, and increased 
survival of the mice tail vein injected with NSCLC cells.
One of the first crucial clinical points in the treatment 
of lung cancer patients is the difficulty of obtaining an 
early diagnosis, which results in high mortality and poor 
prognosis. The patient history, physical examination, 
and radiological imaging studies are the gold standard 
for lung cancer screening. However, these tests are not 
sufficiently accurate for effective cancer diagnosis and 
disease staging [29, 30]. Serum proteins, such as carcino-
embryonic antigen, cytokeratin 19 fragment, cancer 
antigen 125, squamous-cell carcinoma antigen, neuron-
specific enolase, progastrin-releasing peptide, tumour 
M2-pyruvate kinase, and C-reactive protein are potential 
markers for lung cancer, and their levels can signify the 
presence of tumours, facilitate histological analysis, and 
allow prediction of cancer progression. However, due to 
their limited sensitivity and specificity, these potential 
markers are not recommended or encouraged in routine 
clinical practice. Here, we present h-Prune as a potential 
novel marker for the detection of early stage NSCLC, not 
only through its mRNA expression levels in lung cancer 
tissues as demonstrated by gene expression data, but 
also because of its secreted characteristic into peripheral 
blood. In diagnosis, serum cancer markers are even more 
important than tissue markers because they are easily 
procurable for large screenings for early cancer diagnosis. 
H-Prune has never been reported to be a secreted protein 
or body fluid accessible molecule. We found significantly 
higher levels of h-Prune expression in the serum of lung 
cancer patients compared to healthy controls. Early 
stage I or II NSCLC could even be detected with a 79% 
specificity and 93% sensitivity. In the near future, we will 
expand these analyses to investigate whether h-Prune has 
the potential to be developed as diagnostic marker into 
a population-based screening tool and can be useful for 
early diagnosis of NSCLC. 
At this time, h-Prune would represent a selective 
therapeutic target for lung cancer treatment. Thus h-Prune 
inhibitors might prove to be pioneers for their use in 
preclinical studies [31] and can certainly be proposed for 
the prevention and treatment of h-Prune-positive lung 
cancer. 
Wnt-3 gene expression in resected NSCLC was 
statistically associated with high Ki67, low apoptosis, 
and high expression of c-myc and survivin, and its 
overexpression was reported promoting tumor progression 
and poor prognosis in non-small cell lung cancer [32] We 
have demonstrated here that lung cancer patients had also 
high serum levels of Wnt3a. We thus believe that great 
importance should be given by the combination of both 
h-Prune and Wnt3a expression analyses in the serum in 
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those patients with early stage of NSCLC, this approach 
might improve lung cancer diagnosis. This should provide 
helpful information for clinicians in their treatment of lung 
cancer patients, to reduce tumour burden and impair its 
metastatic disease.
In conclusion, our study not only reveals the 
pathological role and the regulatory mechanisms of 
h-Prune in NSCLC, but also indicates its correlation with 
tumour disease. 
MATERIALS AND METHODS
Elisa assay
H-Prune concentrations were determined using 
a commercially available ELISA (Cusabio, Human 
ELISA kit Prune Homology-CSB-EL018831HU, China) 
in according to manufacturer’s instructions. Wnt3a 
concentrations were determined using a commercially 
available ELISA (QAYEE, Human Wnt3a, China) in 
according to kit manufacturer’s instructions.
Study subjects
The study was approved by the Ethics Committee of 
the UOC Clinica Pneumologica SUN and the UOSD Day 
Hospital Oncologico Polmonare della A.O. Ospedali dei 
Colli, plesso Monaldi, (protocol n. 976/2013).
Experimental lung metastasis models
To determine the effects of h-Prune silencing on the 
formation of metastatic lung tumours, experiments were 
carried out using a mouse lung metastasis model. A549_
Luc cells were infected with AdV-Sh-UNR and AdV-Sh-
Prune (100 MOI), and one day later they were harvested, 
washed, and resuspended at a density of 2 ×105 viable 
cells/100 µL sterile PBS. The cells were injected into the 
tail veins of 6-week-old female nude mice. Six mice were 
used in each of the two groups (AdV-Sh-UNR and AdV-
Sh-Prune). The mice were monitored daily and sacrificed 
after 11 months, following standard procedures. Mice 
experiments were approved by “The Institutional Animal 
Care and Ethical Committee of CEINGE – ‘Federico II’ 
University of Naples (Protocol 29, September 30, 2012; 
Dipartimento Sanita` Pubblica Veterinaria D.L. 116/92).
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